Genetically Modified T Cells for the Treatment of ...
The major disadvantage of the system is that it is not yet tested clinically and little is known about its oncogenic potential in vivo. However, a GMPqualified SB transposon system has been approved for a gene therapy clinical trial (NCT) by the Food and .